Enjoy a private dinner with Jared Heyman, General Partner at Pioneer Fund, in San Francisco, CA.
Jared Heyman is a General Partner at Pioneer Fund, a venture fund that pools capital and expertise from the Y Combinator alumni community to invest in top YC startups. Jared is also the Founder & CEO of CrowdMed (www.crowdmed.com), a digital health startup harnessing ‘the wisdom of crowds’ to solve the world’s most difficult medical cases online. The company has raised over $4M in venture capital to date from top-tier Silicon Valley venture funds including NEA, Khosla Ventures, Andreessen Horowitz, Greylock Partners, SV Angel, and Y Combinator. Heyman has spent the past 20+ years as an Internet technology entrepreneur. He founded his first company in college, the online survey firm Infosurv (www.infosurv.com), which he bootstrapped from zero to over $20M in total revenue. He also founded the Infosurv spin-out Intengo (www.gointengo.com) a leading-edge prediction market technology for market research which has also generated millions in revenue. He has been featured on Bloomberg TV, Fox News, USA Today, CBS News, NBC News, the Wall Street Journal, The Economist, Forbes, CNN Online, the Chicago Tribune, Entrepreneur magazine, TechCrunch, BusinessWeek, VentureBeat, Wired, Fast Company, NPR, MedCrunch, New Scientist magazine, and hundreds more. He was also featured on the cover of Inc. magazine in November 2011 and gave a TEDMED talk in September 2014. He has spoken at several major healthcare and technology events, including the Rock Health Innovation Summit, Personalized Medicine World Conference, Exponential Medicine, and CA World.
Heyman was formerly a consultant at Bain & Company and graduated Magna Cum Laude from the University of Texas at Austin with majors in Business Honors and Marketing. He is the lead inventor on multiple US patents related to prediction market technology.
Notice of Updated Buyer Terms of Use
We have recently updated our Buyer Terms of Use. We encourage you to review the revised terms to ensure continued understanding and compliance. By continuing to use our platform, you acknowledge and agree to the updated terms. View the updated Terms of Use